Loading...

Qilian International Holding Group Limited

QLINASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$5.41
$-0.20(-3.57%)

Qilian International Holding Group Limited (QLI) Stock Overview

Explore Qilian International Holding Group Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.2/100

Key Financials

Market Cap38.7M
P/E Ratio-24.86
EPS (TTM)$-1.10
ROE-0.16%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$3.47

QLI Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Qilian International Holding Group Limited (QLI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $3.47.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -24.86 and a market capitalization of 38.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for QLIStats details for QLI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for QLIAnalyst Recommendations details for QLI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

CEO

Chen Xin

Employees

298

Headquarters

Jiuquan Eco & Tech Dev Zn, Jiuquan

Founded

2021

Frequently Asked Questions

;